Skip to main content
. 2016 Aug 5;7(34):54215–54227. doi: 10.18632/oncotarget.11090

Figure 4. The protein level of Rab35 is increased in the substantia nigra (SN) of MPTP-treated mice, rotenone-treated mice, (G2019S) LRRK2 or (R1441C) LRRK2 transgenic mice, but not in the SN of SCA3 transgenic mice.

Figure 4

(A) Treatment with MPTP significantly increased protein level of Rab35 in the SN. Quantification of Rab35 protein measured by the use of a densitometer showed that MPTP administration induced an increase in protein level of Rab35 in the SN with a dose-dependent manner. (B) The protein level of Rab35 was increased in the SN of rotenone-treated mice. (C) In contrast to striatum (ST), the expression of Rab35 protein in the SN was significantly upregulated in (G2019S) LRRK2 transgenic mouse. (D) The protein level of Rab35 in the SN was increased in (R1441C) LRRK2 transgenic mouse. (E) There was no significant difference in protein expression of Rab35 between wild-type mouse and SCA3 transgenic mouse. Each bar represents the mean ± SEM value of four independent experiments. *p < 0.05, **p < 0.01 compared to control groups.